COMPANY  UPDATES

November 16, 2020

Atropos is one of the companies selected for Nature Biotechnology’s new article on senolytics. Read more >>

August 13, 2020

We are excited to collaborate with The Estée Lauder Companies in a joint development agreement to discover senomodulators!  >>

June 11, 2020

Initial round of high throughput screening with Scripps Research Institute is completed and senosuppressor hits are currently being evaluated at Atropos.

April 29, 2020

Atropos is pleased to announce the capital support from Incite and LC Global Partners helping us to pursue our goals to identify senomodulators.

Atropos Founder is interviewed by James Ruhle on The Simple Biotech Podcast. Andy talks about aging, Atropos, and provides an analogy to COVID-19. Many thanks to James for hosting.  >>

March 17, 2020

Atropos is pleased to announce the recruitment of two individuals, Ethan Than MBA and Harsha Agarwal PhD, to our Business Development and Laboratory efforts. >>

Atropos is pleased to announce the recent submission of our non-provisional patent by WSGR describing the FATES platform for identification of senomodulators.

February 26, 2020

Atropos welcomes William D. Tap to the Board of Directors. Bill is the Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center. He has experience in translational medicine and drug development.   >>

September 11, 2019

Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients  >>

January 13, 2019

Atropos Selected as Finalist to Present in RESI San Francisco 2019 West Coast Pitch Challenge  >>

©2018 by Atropos Therapeutics Inc.. Proudly created with Wix.com